An article from
Dive Brief
The RNA-focused biotech shed 30% of its market value amid growing investor concerns about its main drug business.
Published July 30, 2026
Jacob Bell/BioPharma Dive
Alnylam plunges as earnings deliver ‘one-two punch’
The RNA-focused biotech shed 30% of its market value — or close to $12 billion — amid growing investor concerns about its main drug business.
TL;DRAI
Alnylam cut TTR amyloidosis drug revenue guidance by $200M after pent-up demand normalized, causing a 30% stock plunge ($12B market cap loss). Competitive TTR market pressures and trial setbacks expose guidance risks in high-stakes biotech portfolios, signaling importance of conservative forecasting amid volatile market dynamics.
407 words~2 min read
